Kainomyx, Inc.
Kainomyx is a platform company leveraging its deep understanding of cytoskeletal biology to discover and develop novel therapeutics for veterinary, agricultural, and human diseases. Their mission is to find, develop, and commercialize medicines that enhance the quality of life for humans, animals, and agriculture crops, using valuable cytoskeletal drug targets and cutting-edge small-molecule drug discovery technologies. The company is committed to addressing unmet needs through its innovative pipeline of programs.
Industries
Nr. of Employees
small (1-50)
Kainomyx, Inc.
Products
Novel Therapeutics for Malaria
Develops drugs targeting vital parts of Plasmodium function, essential at multiple stages of parasite infection.
Diagnostic Tools for Malaria
Creating sensitive, easy to administer, inexpensive tools to detect silent carriers of malaria.
Therapeutics for Toxoplasmosis
Focuses on addressing toxoplasmosis, affecting one-third of the human population.
Therapeutics for Cryptosporidiosis
Develops treatment for cryptosporidiosis, a leading cause of waterborne disease in the USA.
Therapeutics for Chagas Disease
Works on treatments for Chagas disease, aiming to address cardiac, digestive, and neurological issues.
Therapeutics for Leishmaniasis
Engages in creating treatments for leishmaniasis, affecting 6 million people in 98 countries.
Novel Therapeutics for Malaria
Develops drugs targeting vital parts of Plasmodium function, essential at multiple stages of parasite infection.
Diagnostic Tools for Malaria
Creating sensitive, easy to administer, inexpensive tools to detect silent carriers of malaria.
Therapeutics for Toxoplasmosis
Focuses on addressing toxoplasmosis, affecting one-third of the human population.
Therapeutics for Cryptosporidiosis
Develops treatment for cryptosporidiosis, a leading cause of waterborne disease in the USA.
Therapeutics for Chagas Disease
Works on treatments for Chagas disease, aiming to address cardiac, digestive, and neurological issues.
Therapeutics for Leishmaniasis
Engages in creating treatments for leishmaniasis, affecting 6 million people in 98 countries.
Services
End-to-end R&D services to identify, characterize, and advance small-molecule modulators of cytoskeletal targets for antiparasitic and cross-sector applications.
End-to-end R&D services to identify, characterize, and advance small-molecule modulators of cytoskeletal targets for antiparasitic and cross-sector applications.
Expertise Areas
- Cytoskeletal biology and molecular motors
- Small-molecule drug discovery
- Antiparasitic therapeutics
- Biophysical assay development and live imaging
Key Technologies
- Target-based small-molecule discovery
- In vitro motility assays
- High-resolution fluorescence/live imaging
- Molecular and biophysical characterization of molecular motors
News & Updates
Kainomyx Research Laboratories India Pvt. Ltd., a wholly-owned subsidiary of Kainomyx Inc. launches in India.
Kainomyx was recognized as one of the top 5 out of 139 global startup companies tackling malaria.
Kainomyx secured $6 million in a financing round to promote its malaria therapeutics program and advance its pipeline.
Kainomyx received a $1.97 million grant from the Bill and Melinda Gates Foundation.
Kainomyx was featured in Forbes' Impact 50 article about investors seeking profit and pushing for change.
Kainomyx relocated to a new space at 3160 Porter Drive, Palo Alto, CA.
Kainomyx Research Laboratories India Pvt. Ltd., a wholly-owned subsidiary of Kainomyx Inc. launches in India.
Kainomyx was recognized as one of the top 5 out of 139 global startup companies tackling malaria.
Kainomyx secured $6 million in a financing round to promote its malaria therapeutics program and advance its pipeline.
Kainomyx received a $1.97 million grant from the Bill and Melinda Gates Foundation.
Kainomyx was featured in Forbes' Impact 50 article about investors seeking profit and pushing for change.
Kainomyx relocated to a new space at 3160 Porter Drive, Palo Alto, CA.